GlassScriptPhysician profile
James D Campbell
NPI 1932185212
$1,884.82
in general payments reported to CMS, 2019-2025
14 companies · $213 in 2025
The $213 reported for 2025 was more than what 81% of Emergency Medical Services providers received nationally (typical 2025 total: $70.35).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $18.22 · 2021: $92.88 · 2022: $74.80 · 2023: $611 · 2024: $594 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,202 · Education: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,202.14 |
| Education | $215.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $464.37 | 2021-2023 | Ubrelvy, Qulipta, Vraylar |
| Teva Pharmaceuticals USA, INC. | $341.91 | 2024-2025 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $241.13 | 2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.65 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $124.47 | 2023 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $115.59 | 2024 | Xifaxan |
| Allergan, INC. | $115.12 | 2019 | |
| Steris Corporation | $89.04 | 2025 | |
| Glaxosmithkline, LLC. | $78.75 | 2022-2023 | Trelegy Ellipta |
| Kowa Pharmaceuticals America, INC. | $65.23 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $64.15 | 2022-2023 | Quviviq |
| Mannkind Corporation | $22.56 | 2023 | Afrezza |
| Almatica Pharma LLC | $19.63 | 2025 | Loreev Xr |
| Amarin Pharma, INC. | $18.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.